Encodia

Encodia is a biotechnology startup founded in 2015 with the slogan "Unlimit Biology™". The company is pioneering an innovative Next-Gen digital proteomics platform to democratize protein sequencing. Encodia's ambition is to simplify and universalize protein sequencing by leveraging a unique reverse-translation technology that transforms peptide sequences into DNA. This DNA can then be analyzed using NGS DNA sequencers, opening avenues for revolutionary proteomics research that was previously impractical or cost-prohibitive with existing technologies. The latest milestone for Encodia was a significant $75.00M Series C investment on 27 January 2021. This round of funding saw the participation of esteemed investors including Arch Venture Partners, GV, Biomatics Capital Partners, Tao Capital Partners, Alexandria Venture Investments, Decheng Capital, Deerfield Management, Nan Fung Life Sciences, and Northpond Ventures. The company is headquartered in the United States. Encodia's disruptive technology and strong investor backing position it as a promising player in the biotechnology landscape, with the potential to revolutionize proteomics research and contribute to significant advancements in the field.